Table 1.
Baseline details of the participants.
| Variable | Value (N = 84) |
|---|---|
| Age in years-No (%) | |
| Median (Range) | 52.5 (21–75) |
| Non-Elderly | 61 (72.6) |
| Elderlyb | 23 (27.4) |
| Gender-No (%) | |
| Male | 38 (45.2) |
| Female | 46 (54.8) |
| ECOG PS-No (%) | |
| 1 | 41 (48.8) |
| 2 | 28 (33.3) |
| 3 | 9 (10.7) |
| 4 | 6 (7.1) |
| Disease site-No (%) | |
| Breast | 22 (26.2) |
| Lung (NSCLC) | 45 (53.6) |
| Lung (SCLC) | 1 (1.2) |
| Gastrointestinal | 9 (10.7) |
| Others | 7 (8.3) |
| NSCLC-Molecular types-No (%)a | |
| EGFR mutation | 36 (42.9) |
| ALK rearrangement | 3 (3.6) |
| No mutation | 7 (8.3) |
| Breast cancer-Molecular types-No (%)a | |
| TNBC | 11 (13.1) |
| ER/PR+ & Her-2 negative | 9 (10.7) |
| ER/PR- & Her-2 positive | 1 (1.2) |
| ER/PR- & Her-2 positive | 1 (1.2) |
| Number prior therapies-No (%) | |
| Nil | 2 (2.4) |
| 1 | 43 (51.2) |
| 2 | 20 (23.8) |
| 3 | 15 (17.9) |
| ≥4 | 4 (4.8) |
| LMC diagnosis-No (%) | |
| Confirmed | 52 (61.9) |
| Probable | 32 (38.1) |
| Extracranial disease status at diagnosis-No (%) | |
| Progressive disease | 39 (46.4) |
| Stable disease | 31 (36.9) |
| Partial response | 8 (9.5) |
| Complete response | 5 (6) |
| Missing data | 1 (1.2) |
ECOG PS- Eastern Cooperative Oncology Group Performance Status. NSCLC- Non small cell lung cancer, SCLC–small cell lung cancer, EGFR-epidermal growth factor receptor, ALK- Anaplastic lymphoma kinase, ER-Estrogen receptor, PR-Progesterone receptor, Her-2-human epidermal growth factor receptor 2, LMC-Leptomeningeal carcinomatosis.
a
Restrict to 22 patients with breast cancer and 45 patients with NSCLC.
b
‘Elderly’ was defined as age >60 years.